Skip to main content
Top
Published in: Tumor Biology 5/2012

01-10-2012 | Research Article

Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma

Authors: Maria Kowalska, Joanna Tajer, Magdalena Chechlinska, Malgorzata Fuksiewicz, Beata Kotowicz, Małgorzata Syczewska, Jan Walewski, Janina Kaminska

Published in: Tumor Biology | Issue 5/2012

Login to get access

Abstract

Current standard diagnostic methods do not identify patients with Hodgkin lymphoma (HL), who are at high risk of failure after the first-line treatment. In HL patients, serum cytokine levels are frequently elevated and correlate with clinical and pathological features of the disease as well as with disease-free survival and overall survival. The aim of this study was to investigate if pretreatment serum cytokine and cytokine receptor concentrations evaluated by discriminant analysis could be predictive of response to standard first-line treatment in HL. The study involved 48 previously untreated patients with histologically confirmed classical HL and no EBV infection. Treatment included chemotherapy and involved field radiotherapy or radiotherapy alone. At the end of treatment, 71 % of patients reached complete response (CR), and 29 %, in partial response. To identify parameters predictive of nonachievement of CR after the first-line treatment, the discriminant analysis was used. The following variables were included in the analysis: clinical stage, sex, age, histologic subtype, bulky mediastinal mass, systemic symptoms and the number of involved nodal areas, lactate dehydrogenase (LDH) activity, and serum levels of 12 cytokines/cytokine receptors. The resulting classifying function assigned a discriminant power to the following variables: the levels of vascular endothelial growth factor, interleukin-8, macrophage colony stimulating factor, basic fibroblast growth factor, soluble tumor necrosis factor receptor I, and LDH activity. The accuracy of predicting CR and non-CR was 94 and 43 %, respectively.
Literature
1.
go back to reference Cote GM, Canellos GP. Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy? Curr Hematol Malig Rep. 2011;6:180–6.CrossRefPubMed Cote GM, Canellos GP. Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy? Curr Hematol Malig Rep. 2011;6:180–6.CrossRefPubMed
2.
go back to reference Gorschluter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol. 1995;6:477–82.PubMed Gorschluter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol. 1995;6:477–82.PubMed
3.
go back to reference Vener C, Guffanti A, Pomati M, Colombi M, Alietti A, La Targia ML, et al. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma. 2000;37:333–40.PubMed Vener C, Guffanti A, Pomati M, Colombi M, Alietti A, La Targia ML, et al. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma. 2000;37:333–40.PubMed
4.
go back to reference Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:1732–40.CrossRefPubMed Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:1732–40.CrossRefPubMed
6.
go back to reference Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283–97.CrossRefPubMed Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283–97.CrossRefPubMed
7.
go back to reference Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin’s disease patients. Brit J Cancer. 1998;77:2357–62.CrossRefPubMedPubMedCentral Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin’s disease patients. Brit J Cancer. 1998;77:2357–62.CrossRefPubMedPubMedCentral
8.
go back to reference Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute Experience. Med Oncol. 2000;17:59–63.CrossRefPubMed Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute Experience. Med Oncol. 2000;17:59–63.CrossRefPubMed
9.
go back to reference Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004;28:595–604.CrossRefPubMed Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004;28:595–604.CrossRefPubMed
10.
go back to reference Rautert R, Schinköthe T, Franklin J, Weihrauch M, Boll B, Pogge E, et al. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma. 2008;49:2091–8.CrossRefPubMed Rautert R, Schinköthe T, Franklin J, Weihrauch M, Boll B, Pogge E, et al. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk Lymphoma. 2008;49:2091–8.CrossRefPubMed
11.
go back to reference Gaiolla R, Domingues MAC, Niero-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med. 2011;135:483–9.PubMed Gaiolla R, Domingues MAC, Niero-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med. 2011;135:483–9.PubMed
12.
go back to reference Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5:27–37.PubMed Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5:27–37.PubMed
13.
go back to reference Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005;23:9208–18.CrossRefPubMed Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005;23:9208–18.CrossRefPubMed
14.
go back to reference Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6.PubMed Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–6.PubMed
15.
go back to reference Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMed
16.
go back to reference Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009;206:1089–102.CrossRefPubMedPubMedCentral Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009;206:1089–102.CrossRefPubMedPubMedCentral
17.
go back to reference Rueda A, Olmos D, Villareal V, Torres E, Pajares BI, Alba E. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma. 2007;7:400–5.CrossRefPubMed Rueda A, Olmos D, Villareal V, Torres E, Pajares BI, Alba E. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma. 2007;7:400–5.CrossRefPubMed
18.
go back to reference Kowalska M, Kaminska J, Fuksiewicz M, Kotowicz A, Siedlecka JT, et al. Serum VEGF and bFGF levels in patients with Hodgkin's lymphoma. Nowotwory J Oncol. 2007;57:179e–82e. http://www.nowotwory.edu.pl/. Kowalska M, Kaminska J, Fuksiewicz M, Kotowicz A, Siedlecka JT, et al. Serum VEGF and bFGF levels in patients with Hodgkin's lymphoma. Nowotwory J Oncol. 2007;57:179e–82e. http://​www.​nowotwory.​edu.​pl/​.​
19.
go back to reference Foss HD, Herbst H, Gottstein S, Demel G, Araujó I, Stein H. Interleukin-8 in Hodgkin's disease. Am J Pathol. 1996;148:1229–36.PubMedPubMedCentral Foss HD, Herbst H, Gottstein S, Demel G, Araujó I, Stein H. Interleukin-8 in Hodgkin's disease. Am J Pathol. 1996;148:1229–36.PubMedPubMedCentral
20.
go back to reference Trümper L, Jung W, Dahl G, Diehl V, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol. 1994;5 Suppl 1:93–6.CrossRefPubMed Trümper L, Jung W, Dahl G, Diehl V, Gause A, Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol. 1994;5 Suppl 1:93–6.CrossRefPubMed
21.
go back to reference Kowalska M, Kaminska J, Fuksiewicz M, Kotowicz B, Siedlecka A, Tajer J, et al. Pro-inflammatory and inhibitory cytokines in the sera of patients with Hodgkin's lymphoma. Nowotwory J Oncol. 2007;57:162e–7e. http://www.nowotwory.edu.pl/. Kowalska M, Kaminska J, Fuksiewicz M, Kotowicz B, Siedlecka A, Tajer J, et al. Pro-inflammatory and inhibitory cytokines in the sera of patients with Hodgkin's lymphoma. Nowotwory J Oncol. 2007;57:162e–7e. http://​www.​nowotwory.​edu.​pl/​.​
22.
go back to reference Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798–801.CrossRefPubMed Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798–801.CrossRefPubMed
23.
24.
go back to reference Paietta E, Racevskis J, Stanley ER, Andreeff M, Papenhausen P, Wiernik PH. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res. 1990;50:2049–55.PubMed Paietta E, Racevskis J, Stanley ER, Andreeff M, Papenhausen P, Wiernik PH. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res. 1990;50:2049–55.PubMed
25.
go back to reference Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875–85.CrossRefPubMedPubMedCentral Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875–85.CrossRefPubMedPubMedCentral
26.
go back to reference Janowska-Wieczorek A, Belch AR, Jacobs A, Bowen D, Padua RA, Paietta E, et al. Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. Blood. 1991;77:1796–803.PubMed Janowska-Wieczorek A, Belch AR, Jacobs A, Bowen D, Padua RA, Paietta E, et al. Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. Blood. 1991;77:1796–803.PubMed
27.
go back to reference Kowalska M, Tajer J, Chechlinska M, Fuksiewicz M, Kotowicz B, Kaminska J, et al. Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. Med Oncol. 2011 Jun 30. [Epub ahead of print]. Kowalska M, Tajer J, Chechlinska M, Fuksiewicz M, Kotowicz B, Kaminska J, et al. Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. Med Oncol. 2011 Jun 30. [Epub ahead of print].
28.
go back to reference Metkar SS, Naresh KN, Manna PP, Srinivas V, Advani SH, Nadkarni JJ. Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia. Am J Hematol. 2000;65:105–10.CrossRefPubMed Metkar SS, Naresh KN, Manna PP, Srinivas V, Advani SH, Nadkarni JJ. Circulating levels of TNF alpha and TNF receptor superfamily members in lymphoid neoplasia. Am J Hematol. 2000;65:105–10.CrossRefPubMed
29.
go back to reference Kowalska M, Kaminska J, Fuksiewicz M, Kotowicz A, Siedlecka JT, et al. Serum sIL-2Rα, sTNF RI and sTNF RII concentrations in patients with Hodgkin's lymphoma. Nowotwory J Oncol. 2007;57:98e–102e. http://www.nowotwory.edu.pl/. Kowalska M, Kaminska J, Fuksiewicz M, Kotowicz A, Siedlecka JT, et al. Serum sIL-2Rα, sTNF RI and sTNF RII concentrations in patients with Hodgkin's lymphoma. Nowotwory J Oncol. 2007;57:98e–102e. http://​www.​nowotwory.​edu.​pl/​.​
30.
go back to reference Boll B, Borchmann P, Topp MS, Hanel M, Reiners KS, Engert A, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2009;148:480–90.CrossRefPubMed Boll B, Borchmann P, Topp MS, Hanel M, Reiners KS, Engert A, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2009;148:480–90.CrossRefPubMed
Metadata
Title
Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma
Authors
Maria Kowalska
Joanna Tajer
Magdalena Chechlinska
Malgorzata Fuksiewicz
Beata Kotowicz
Małgorzata Syczewska
Jan Walewski
Janina Kaminska
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0432-1

Other articles of this Issue 5/2012

Tumor Biology 5/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine